Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.

Autor: Frey MK; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Kopparam RV; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Ni Zhou Z; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Fields JC; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Buskwofie A; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Carlson AD; Genetic Risk Assessment Program, Weill Cornell Medicine, New York, New York., Caputo T; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Holcomb K; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York., Chapman-Davis E; Division of Gynecologic Oncology, Weill Cornell Medicine, New York, New York.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2019 Mar 01; Vol. 125 (5), pp. 690-697. Date of Electronic Publication: 2018 Nov 27.
DOI: 10.1002/cncr.31856
Abstrakt: Background: Genetic assessment in Ashkenazi Jewish (AJ) patients often is limited to BRCA1/2 founder mutation testing. With access to time-efficient and cost-efficient multigene panel testing, some advocate expanding genetic testing in this population. However, to the best of the authors' knowledge, rates of nonfounder BRCA1/2 mutations and mutations in cancer-associated genes other than BRCA1/2 among AJ are not known. In the current study, the authors sought to assess the prevalence of mutations other than BRCA1/2 founder mutations among AJ patients undergoing genetic assessment.
Methods: The authors reviewed the medical records for all AJ patients who underwent genetic assessment at a single institution between June 2013 and December 2016. Mutations were categorized as 1) BRCA1/2 AJ founder mutations (BRCA1 185delAG, BRCA1 5382insC, or BRCA2 6174delT); 2) nonfounder BRCA1/2 mutations; or 3) mutations in non-BRCA1/2 cancer-associated genes.
Results: A total of 732 AJ patients underwent genetic assessment. Of these, 371 patients (51%) had a personal history of breast or ovarian cancer, 540 patients (73.8%) had a family history of breast cancer, and 132 patients (18%) had a family history of ovarian cancer. In the study population, 101 patients (13.8%) were found to have a pathogenic mutation, 78 patients (10.7%) had a BRCA1/2 founder mutation, 3 patients (0.4%) had a nonfounder BRCA1/2 mutation, and 20 patients (2.7%) had a mutation in a non-BRCA1/2 cancer-associated gene. Non-BRCA1/2 cancer-associated genes harboring mutations included RAD51D, TP53, mutS homolog 6 (MSH6), checkpoint kinase 2 (CHEK2), adenomatous polyposis coli (APC), and Fanconi anemia group C protein (FANCC).
Conclusions: Among AJ patients found to have a pathogenic mutation on genetic assessment, approximately 22.8% had a mutation that would be missed with BRCA1/2 AJ founder mutation testing. Comprehensive multigene panel sequencing can provide clinically relevant genetic information for AJ patients and should be considered for genetic assessment in this population.
(© 2018 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: